Catherine Berset

653 total citations
12 papers, 416 citations indexed

About

Catherine Berset is a scholar working on Molecular Biology, Infectious Diseases and Genetics. According to data from OpenAlex, Catherine Berset has authored 12 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Infectious Diseases and 3 papers in Genetics. Recurrent topics in Catherine Berset's work include Chronic Lymphocytic Leukemia Research (3 papers), Fungal and yeast genetics research (3 papers) and HIV/AIDS drug development and treatment (3 papers). Catherine Berset is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Fungal and yeast genetics research (3 papers) and HIV/AIDS drug development and treatment (3 papers). Catherine Berset collaborates with scholars based in Switzerland, Netherlands and United States. Catherine Berset's co-authors include Michael Altmann, Hans Trachsel, Siamak Djafarzadeh, Andreas Zurbriggen, Stefan Lanker, Alcide Barberis, Urs Lüthi, Hanne Hawle, Curt Wittenberg and Peter Griač and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Catherine Berset

12 papers receiving 410 citations

Peers

Countries citing papers authored by Catherine Berset

Since Specialization

Citations

This map shows the geographic impact of Catherine Berset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Berset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Berset more than expected).

Fields of papers citing papers by Catherine Berset

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Berset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Berset. The network helps show where Catherine Berset may publish in the future.

Co-authorship network of co-authors of Catherine Berset

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Berset. A scholar is included among the top collaborators of Catherine Berset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Berset. Catherine Berset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	716P Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study 2020 ·Annals of Oncology ·Frank Stenner, Richard Cathomas, Christian Rothermundt, Julian Schardt, Anna Patrikidou, Deborah Zihler, Andreas Erdmann, (unknown), D. Dietrich, Catherine Berset, Gilles Godar, Dominik Berthold, Heinz Läubli	2
2	The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13) 2016 ·Blood ·Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, Catherine Berset, (unknown), Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander	13
3	Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08 2015 ·European Journal of Cancer ·Khalil Zaman, (unknown), Christoph Mamot, (unknown), Christoph Rochlitz, Andreas Mueller, Catherine Berset, (unknown), Lucien Perey, (unknown), Hanne Hawle, (unknown), Patrick Neven	43
4	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08) 2015 ·Haematologica ·Christoph Driessen, Marianne Kraus, Markus Joerger, Hilde Rosing, Jürgen Bader, Felicitas Hitz, Catherine Berset, Alexandros Xyrafas, Hanne Hawle, Grégoire Berthod, Herman S. Overkleeft, Cristiana Sessa, Alwin D. R. Huitema, Thomas Pabst, Roger von Moos, Dagmar Hess, Ulrich Mey	47
5	SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity. 2012 ·Blood ·Christoph Driessen, Dagmar Hess, Thomas Pabst, Sarah R. Haile, Markus Joerger, Roger von Moos, Catherine Berset, Susanne Crowe, Hilde Rosing, Herman S. Overkleeft, C. Sessa, Marianne Kraus	1
6	Yeast as a screening tool 2005 ·Drug Discovery Today Technologies ·Alcide Barberis, (unknown), Catherine Berset, (unknown), Urs Lüthi	43
7	The ISG15 Isopeptidase UBP43 Is Regulated by Proteolysis via the SCFSkp2 Ubiquitin Ligase 2004 ·Journal of Biological Chemistry ·Sara Tokarz, Catherine Berset, (unknown), Kevin M. Friedman, Keiichi I. Nakayama, Keiko Nakayama, Dong‐Er Zhang, Stefan Lanker	45
8	RNA-binding activity of translation initiation factor eIF4G1 from Saccharomyces cerevisiae 2003 ·RNA ·Catherine Berset, Andreas Zurbriggen, Siamak Djafarzadeh, Michael Altmann, Hans Trachsel	58
9	Transferable Domain in the G ₁ Cyclin Cln2 Sufficient To Switch Degradation of Sic1 from the E3 Ubiquitin Ligase SCF ^Cdc4 to SCF ^Grr1 2002 ·Molecular and Cellular Biology ·Catherine Berset, Peter Griač, (unknown), (unknown), Curt Wittenberg, Stefan Lanker	40
10	The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae 1998 ·Proceedings of the National Academy of Sciences ·Catherine Berset, Hans Trachsel, Michael Altmann	119
11	The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae (cell cycleystarvationyprotein degradation) 1998 ·Catherine Berset, Hans Trachsel, Michael Altmann	4
12	The research situation with regard to natural food colourants. 1990 ·Catherine Berset	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact